Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


January 17, 2001 17 January, 2001

Pheromone Sciences Corp Announces Positive Clinical Trial Results


Pheromone Sciences Corp (CDNX:PHS), today announced positive clinical trial results on its lead product, the PSC Fertility Monitor'. The trial was conducted with 21 normal healthy women at Toronto General Hospital under the direction of Dr. Robert Casper, Professor and Head of Reproductive Sciences at the University of Toronto. The trial compared the efficacy of the PSC Fertility Monitor' to current techniques for detecting fertility and ovulation. Results confirmed that the PSC Fertility Monitor' predicted ovulation within +/- 1.38 days of the actual date, while also providing women with up to four days advance notice of ovulation. This accuracy compares very favourably to other ovulation or fertility testing technologies and methods currently in use, none of which have the capacity to provide users with the same specific advance notice.

In commenting on the outcome, Dr. Casper stated, "The results of this trial suggest that the PSC Fertility Monitor' represents a major advance in the field of fertility and ovulation prediction. The PSC Fertility Monitor' provides more advance notice than other available methods with reliable accuracy, in a convenient, non-invasive manner. This would also provide a new tool for couples engaged in family planning".

The PSC Fertility Monitor' offers a new user- friendly option in family planning. This product, which is housed in a modern styled wristwatch like device with an LCD readout, is worn at night during sleeping hours. The PSC Fertility Monitor' is a proprietary, non-invasive device which predicts ovulation by measuring ion changes on the surface of the skin. The device incorporates an interactive microprocessor combined with a biosensor enabling it to take up to 12 daily measurements from the skin surface and to evaluate the data in order to predict the status of the user as being not-fertile, fertile or ovulating. Results can be viewed at any time on the LCD screen of the device or as a computer- generated graphical printout for medical professionals.

"This is another significant milestone successfully achieved," said Christopher Neuman, President and Chief Executive Officer of Pheromone Sciences. "We remain committed to our goal of completing U.S. regulatory submissions and concluding a strategic alliance for the marketing and distribution rights for this product come year end."

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

443 King Street East Toronto, Ont, Canada M5A 1L5 tel: (416) 861-9854 fax: (416) 861-9950

INVESTOR CONTACT Lorne Woods 1-(800) 937-3095

Nick Borrelly (604) 872-2012 mailto:investor@pheromonesciences.com http://www.pheromonesciences.com